Pharma Mar says test of potential coronavirus drug promising
Reuters
Published Mar 13, 2020 08:36
Pharma Mar says test of potential coronavirus drug promising
MADRID (Reuters) - Spanish pharmaceutical company Pharma Mar (MC:PHMR) said on Friday tests carried out in test tubes with its cancer drug Aplidin on samples of a virus similar to the COVID-19 coronavirus were encouraging.
Investigators from Spain's biotech centre Centro Nacional de Biotecnologia del Centro Superior de Investigaciones Cientificas showed Aplidin has a positive effect on multiplication and propagation of the virus, Pharma Mar said in a statement on Friday.
The company will contact regulatory authorities to analyse the possibility of testing the drug on patients with the COVID-19 coronavirus.
Aplidin is marketed in countries like Australia as a treatment for certain blood cancers.
Get The App
Written By: Reuters
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.